Nitrosamine impurities

To protect patients and strengthen the global medicines supply chain, USP is providing tools and solutions to analyze and monitor emerging impurities in the drug supply.

Starting in 2018 the presence of nitrosamine impurities was identified in some angiotensin II receptor blocker (ARBs) used to treat high blood pressure and heart failure. Subsequently, nitrosamines impurities have been found in additional drug products, leading to a major effort by regulators and industry to reduce or eliminate their presence in the drug supply.

Companies are responsible for understanding their manufacturing processes, which includes identifying and preventing the presence of unacceptable impurities. This involves developing new predictive approaches, along with using suitable methods to detect and control these impurities as well as others that may arise when making changes to manufacturing processes.

USP is supporting manufacturers and regulators with tools and solutions for testing, assessing risk and understanding potential sources related to nitrosamine impurities.

For additional information or questions about USP’s efforts related to nitrosamine impurities, contact

nitrosamine reference standards
nitrosamine reference standards

Two new Nitrosamine Impurities

Discover the value beyond the vial

Standards | Process | Service

Learn more

Genotoxic impurities webinar

Ed Gump, Ph.D., Vice President, USP Small Molecules
Pharmaceutical Technology Editors' Series Webcast
"Genotoxic Impurities and Drug Quality--Lessons from the Nitrosamine Contamination Crisis"
July 14, 2020

Register for the recorded webinar

New GC 1469 Nitrosamine Impurities – PF46

New General Chapter – 1469 Nitrosamine Impurities – Open for Comment

To protect patients from the adverse effects of nitrosamines as impurities, USP has proposed a new general chapter <1469> Nitrosamine Impurities in Pharmacopeial Forum 46(5) [Sep.−Oct. 2020]. Log in to PF to access and comment by November 30, 2020

Access PF now